

# Drug Policy:

## Rybrevant™ (amivantamab-vmjw)

<b>POLICY NUMBER</b> UM ONC_1441	<b>SUBJECT</b> Rybrevant™ (amivantamab-vmjw)	<b>DEPT/PROGRAM</b> UM Dept	<b>PAGE 1 of 3</b>
<b>DATES COMMITTEE REVIEWED</b> 07/14/21, 11/15/21, 05/11/22, 06/08/22, 05/10/23, 05/08/24, 07/10/24, 10/09/24	<b>APPROVAL DATE</b> October 9, 2024	<b>EFFECTIVE DATE</b> October 25, 2024	<b>COMMITTEE APPROVAL DATES</b> 07/14/21, 11/15/21, 05/11/22, 06/08/22, 05/10/23, 05/08/24, 07/10/24, 10/09/24
<b>PRIMARY BUSINESS OWNER:</b> UM		<b>COMMITTEE/BOARD APPROVAL</b> Utilization Management Committee	
<b>NCQA STANDARDS</b> UM 2		<b>ADDITIONAL AREAS OF IMPACT</b>	
<b>CMS REQUIREMENTS</b>	<b>STATE/FEDERAL REQUIREMENTS</b>	<b>APPLICABLE LINES OF BUSINESS</b> Commercial, Exchange, Medicaid	

### I. PURPOSE

To define and describe the accepted indications for Rybrevant (amivantamab-vmjw) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

### II. INDICATIONS FOR USE/INCLUSION CRITERIA

#### A. Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided:

1. The requested medication was used within the last year, **AND**
2. The member has not experienced disease progression and/or no intolerance to the requested medication, **AND**
3. Additional medication(s) are not being added to the continuation request.

#### B. Non-Small Cell Lung Cancer (NSCLC)

1. Rybrevant (amivantamab-vmjw) may be used as monotherapy for members with locally advanced/metastatic/recurrent Non-Small Cell Lung Cancer (NSCLC), who have had disease progression on prior platinum- based therapy, with or without prior tyrosine kinase inhibitors/immunotherapy, and the cancer is positive for an EGFR exon 20 insertion mutation (confirmed by a standardized test).

2. Rybrevant (amivantamab-vmjw) may be used in adult members in combination with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations (confirmed by a standardized test).
3. Rybrevant (amivantamab-vmjw) may be used in adult members in combination with carboplatin and pemetrexed for locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor [i.e., Tagrisso (osimertinib), Tarceva (erlotinib)].
4. Rybrevant (amivantamab-vmjw) may be used in adult members in combination with Lazcluze (lazertinib) for the first-line treatment of locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations (confirmed by a standardized test).

### III. EXCLUSION CRITERIA

- A. Disease progression while taking Rybrevant (amivantamab-vmjw).
- B. Dosing exceeds single dose limit of Rybrevant (amivantamab-vmjw) 2100 mg (for weight greater than or equal to 80 kg) or 1750 mg (for weight less than 80 kg).
- C. Investigational use of Rybrevant (amivantamab-vmjw) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
  1. Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
  2. Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
  3. Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
  4. Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
  5. That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
  6. That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
  7. That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

### IV. MEDICATION MANAGEMENT

- A. Please refer to the FDA label/package insert for details regarding these topics.

### V. APPROVAL AUTHORITY

- A. Review – Utilization Management Department

- B. Final Approval – Utilization Management Committee

## VI. ATTACHMENTS

- A. None

## VII. REFERENCES

- A. Park K, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. *J Clin Oncol*. 2021 Oct 20;39(30):3391-3402.
- B. Cho BC, et al. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. *Future Oncol*. 2022 Feb;18(6):639-647. doi: 10.2217/fon-2021-0923.
- C. Passaro A, et al; MARIPOSA-2 Investigators. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. *Ann Oncol*. 2024 Jan;35(1):77-90. doi: 10.1016/j.annonc.2023.10.117.
- D. Zhou C, Tang KJ, et al; PAPILLON Investigators. Amivantamab plus Chemotherapy in NSCLC with *EGFR* Exon 20 Insertions. *N Engl J Med*. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441.
- E. Rybrevant prescribing information. Janssen Biotech, Inc. Horsham, PA 2024.
- F. Clinical Pharmacology Elsevier Gold Standard 2024.
- G. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2024.
- H. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2024.
- I. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs Bethesda, MD 2024.
- J. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*. 2014 Apr 20;32(12):1277-80.
- K. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.

